Cargando…
Correction: Correction: Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
Public Library of Science
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9584390/ https://www.ncbi.nlm.nih.gov/pubmed/36264846 http://dx.doi.org/10.1371/journal.pone.0276650 |
| _version_ | 1784813253349605376 |
|---|---|
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9584390 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Public Library of Science |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-95843902022-10-21 Correction: Correction: Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer PLoS One Correction Public Library of Science 2022-10-20 /pmc/articles/PMC9584390/ /pubmed/36264846 http://dx.doi.org/10.1371/journal.pone.0276650 Text en © 2022 The PLOS ONE Staff https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
| spellingShingle | Correction Correction: Correction: Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer |
| title | Correction: Correction: Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer |
| title_full | Correction: Correction: Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer |
| title_fullStr | Correction: Correction: Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer |
| title_full_unstemmed | Correction: Correction: Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer |
| title_short | Correction: Correction: Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer |
| title_sort | correction: correction: phase ii study evaluating 2 dosing schedules of oral foretinib (gsk1363089), cmet/vegfr2 inhibitor, in patients with metastatic gastric cancer |
| topic | Correction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9584390/ https://www.ncbi.nlm.nih.gov/pubmed/36264846 http://dx.doi.org/10.1371/journal.pone.0276650 |
| work_keys_str_mv | AT correctioncorrectionphaseiistudyevaluating2dosingschedulesoforalforetinibgsk1363089cmetvegfr2inhibitorinpatientswithmetastaticgastriccancer |